JAN 0 5 201

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Sh	· · · · · · · · · · · · · · · · · · ·
In re Patent Application of) Group Art Unit: 1615
Didier Hoarau et al.	Examiner: THURMAN K PAGE
Application No.: 10/518,173) Confirmation No.: 5720
Filing Date: December 10, 2004	į
Title: STEALTH LIPID NANOCAPSULES, METHODS FOR THE PREPARATION THEREOF AND USE THEREOF AS A CARRIER FOR ACTIVE PRINCIPLE(S)))))

SECOND INFORMATION DISCLOSURE STATEMENT TRANSMITTAL LETTER

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

 \boxtimes

	Enclosed is a Second Information Disclosure Statement (IDS) and accompanying
form P	TO-1449 for the above-identified patent application.
×	No additional fee for submission of an IDS is required

No additional fee for submission of an IDS is required.

The fee of 180 as set forth in 37 C.F.R. § 1.17(p) is also enclosed.

A statement under 37 C.F.R. § 1.97(e) is also enclosed.

A statement under 37 C.F.R. § 1.97(e), and the fee of 180 as set forth in 37 C.F.R. § 1.17(p) are also enclosed.

Charge _____ to Deposit Account No. 02-4800 for the fee due.

A check in the amount of ______ is enclosed for the fee due.

Charge ______ to credit card for the fee due. Form PTO-2038 is attached.

The Director is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,

BUCHANAN INGERSOLL AND ROONEY PC

Date January 5, 2007

Mary Katherine Baumustur Mary Katherine Baumeister Registration No. 26254

P.O. Box 1404 Alexandria, VA 22313-1404 1737 King Street, Suite 500 Alexandria, VA 22314-2727 703 836 6620

Attorney's Docket No. 1017753-000201



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent Application of

Didier Hoarau et al

Application No.: 10/518,173

Filed: December 10, 2004

For: STEALTH LIPID NANOCAPSULES. METHODS FOR THE PREPARATION)

THEREOF AND USE THEREOF AS A CARRIER FOR ACTIVE PRINCIPLE(S)) Group Art Unit: 1615

Examiner: THURMAN K PAGE

Confirmation No.: 5720

SECOND INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, the accompanying information is being submitted in accordance with 37 C.F.R. §§ 1.97 and 1,98. Applicants request the Examiner's consideration of the documents listed on the accompanying Form PTO-1449.

Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents cited is enclosed. This Statement, Form PTO-1449 and the listed documents are being submitted within three (3) months of the filing or entry of the national stage of this application or before the first Office Action on the merits, whichever is later. Since these documents are being filed within the time period set forth in 37 C.F.R. § 1.97(b), no fee or statement is required.

It is respectfully requested that an Examiner-initialed copy of the accompanying Form PTO-1449 be returned to the undersigned.

Respectfully submitted.

BUCHANAN INGERSOLL & ROONEY PC

Date: January 5, 2007

Registration No. 26254

P.O. Box 1404 Alexandria, VA 22313-1404 703 836 6620

SECOND		App	Application Number 10/518,173												
INFORMATION DISCLOSTERE		Filin	Filing Date			December 10, 2004									
STATEMENT BY APPLICANT (Firs	First Named Inventor			Didier Hoarau et al.									
(use	as many sheets as neces:	necessary): ann		Examiner Name			THURMAN K PAGE								
	(use as many sheets as necessary). 1007			Attorney Docket No. 1017753-000201											
Sheet	1 01 2		/												
	A SOLVER	TRADRUM	U.S	. PATENT	DOCUM	ENT	s								
Examiner Document Kind Cc Initials Number (if know										Issue/Publication Date (MM-DD-YYYY)					
			-								_				
							-				—				
						_									
		_		J							1				
			FORE	IGN PATE	NT DOC	UME	NTS				TATUC				
Examiner Initials			nd Code known)		Country		Date of Publication	Eng. Lang. Summary Partial Translation Translation		Abstract IPER Search Report					
						(IVIIV	A-DD-YYYY)	ation	ation	yave.	at ch	7	act	Spec	
													-		
						<u> </u>				-					
						├			_	-					
						├			├						
						<u> </u>			 	_					
		NON	DATE	NT LITER	ATURE	200	HIMENTS								
Examiner	Include name of the							title	of the	item (h	nok ma	nazin	e iou	mal	
Initials	serial, symposi Steerenberg et al	um, catalog, e	tc.), dat	e, page(s), vo	ume-issue nu	ımber	(s), publisher,	city	and/or	country	where p	oublis	hed.		
	Binding capacity, Pharmaceutics, V	stability a /ol. 40, pp	nd tur . 51-6	nor cell gro 2, 1987, E	owth inhibi Isevier Sci	ition ienc	in vitro", I e Publishe	nte ers	rnatio B.V.,	nal Jo	ourna Nethei	l of rland	ds		
	Newman et al., "C cisplatin encapsu Cancer Chemothe	lated in lo	ng-cir	culating, p	egylated li	ipos	omes (SP	I-07	7) in	tumo					
	Gasco et al., "Dox and in vivo", Phar	orubicine	Englo	bed in Pol	ybutylcyar	noac	crylate Na	noc	apsul		ehavi	our i	n vii	ro	
Examiner					Date										
Signature				Considered			04/15/2008								

Complete if Known

Substitute for form 1449/PTO & 1449B/PTO

Substitute for fe	orm 1449/PTO &	1449B/PTO . •		Complete if Known
SECOND			Application Number	10/518,173
INFORMATION DISCLOSURE			Filing Date	December 10, 2004
STATEMENT BY APPLICANT (use as many sheets agracessary)			First Named Inventor	Didier Hoarau et al.
			Examiner Name	THURMAN K PAGE
		1000	Attorney Docket No.	1017753-000201
Sheet	2 of 2	JAN 0 5 2007 B		
Examiner Initials	serial Klibanov e liposomes	me of the author (in CAF I, symposium, catalog, et et al., "Activity of a depends on the li a et Biophysica Ac	c.), date, page(s), volume-issue or mphipathic poly(ethylen iposome size and is unfa	DOCUMENTS to (when appropriate), title of the item (book, magazine, journal, number(s), publisher, city and/or country where published. e glycol) 5000 to prolong the circulation time of avorable for immunoliposome binding to target", 48, 1991, Elsevier Science Publishers B.V., The